Prolonged treatment with the β3-adrenergic agonist CL 316243 induces adipose tissue remodeling in rat but not in guinea pig: 1) fat store depletion and desensitization of β-adrenergic responses
详细信息 查看全文
- 作者：C. Ferrand (1)
A. Redonnet (1)
D. Prévot (2)
C. Carpéné (2)
C. Atgié (1) - 关键词：β ; adrenoceptor ; Adipose tissue ; Glucose transport ; Lipolysis ; Insulin ; Receptor β ; adrenérgico ; Tejido adiposo ; Transporte de glucosa ; Insulina
- 刊名：Journal of Physiology and Biochemistry
- 出版年：2006
- 出版时间：June 2006
- 年：2006
- 卷：62
- 期：2
- 页码：89-99
- 全文大小：145KB
- 参考文献：1. Abe, H., Minokoshi, Y., and Shimazu, T. (1993): / J. Endocrinol., 139, 479-86. CrossRef
2. Arch, J. R., Ainsworth, A. T., Cawthorne, M. A., Percy, V., Sennit, M. V., Thody, E., Wilson, C., and Wilson, S. (1984): / Nature, 309, 163-65. CrossRef
3. Atgié, C., D’Allaire, F., and Bukowiecki, L. J. (1997): / Am. J. Physiol. Cell Physiol., 42, C1136-C1142.
4. Atgié, C., Faintrenie, G., Carpéné, C., Bukowiecki, L. J., and Gélo?n, A. (1998): / Comp. Biochem. Physiol. 119A, 629-36.
5. Atgié, C., Tavernier, G., D’Allaire, F., Bengtsson, T., Marti, L., Carpéné, C., Lafontan, M., Bukowiecki, L. J. and Lagin, D. (1996): / Am. J. Physiol., 271, R1729-R1738.
6. Bairras, C., Ferrand, C., and Atgié, C. (2003): / J. Physiol. Biochem., 59, 161-68. CrossRef
7. Bloom, J. D., Dutia, M. D., Johnson, B. D., Wissner, A., Burns, M. G., Largis, E. E., Dolan, J. A., and Claus, T. H. (1992): / J. Med. Chem., 35, 3081-084. CrossRef
8. Bour, S., Visentin, V., Prévot, D., and Carpéné, C. (2003). / J. Physiol. Biochem., 59, 169-75. CrossRef
9. Carpéne, C., Ambid, L., and Lafontan, M. (1994): / Am. J. Physiol., 266, R896-R904.
10. Carpené, C., Chalaux, E., Lizarbe, M., Estrada, A., Mora, C., Palacin, M., Zorzano, A., Lafontan, M., and Testar, X. (1993). / Biochem. J., 296, 99-05.
11. Chaudry, A., MacKenzie, R. G., Georgic, L. M., and Granneman, J. G. (1994): / Cell Signalling, 6, 457-65. CrossRef
12. Duffaut, C., Bour, S., Prévot, D., Marti, L., Testar, X., Zorzano, A. and Carpéné, C. (2006): / J. Physiol. Biochem., 62, 101-12. CrossRef
13. Granneman, J. G. (1995): / Cell. Signal., 7, 9-5. CrossRef
14. Granneman, J. G., Li, P., Zhu, Z., and Lu, Y. (2005): / Am. J. Physiol. Endocrinol. Metab., 289, E608-E616. CrossRef
15. Green, A. R., Carroll, R. M., and Dobias, S. B. (1996): / Am. J. Physiol., 271, E271-E276.
16. Hausdorff, W. P., Caron, M. G., and Lefkowitz. (1990): / Fed. Am. Soc. Exp. Biol., 4, 2881-891.
17. Himms-Hagens, J. J., Cui., J., Danforth, E., Taajes, D., Langs, S., Waters, B., and Claus, T. (1994): / Am. J. Physiol., 266, R1371-R1382.
18. Howe, R. (1993): / Drugs of the future, 18, 529-49.
19. Issad, T., Combettes, M., Ferré, P. (1995): / Eur. J. Biochem. 234: 108-15. CrossRef
20. Jost, M. M., Jost, P., Klein, J., and Klein, H. H. (2005): / Exp. Clin. Endocrinol. Diabetes, 113, 418-22. CrossRef
21. Lafontan, M. and Berlan, M. (1993): / J. Lipid Res., 34, 1057-091.
22. Lamas, O., Martínez, J.A., and Marti, A. (2003): / J. Physiol. Biochem., 59, 183-92. CrossRef
23. Ligget, S. B., Freedman, N. J., Schwinn, D. A. and Lefkowitz, R. J. (1993): / Proc. Natl. Acad. Sci., 90, 3665-669. CrossRef
24. Lipworth, B.J. (1996): / Br. J. Clin. Pharmacol., 42:291-00. CrossRef
25. Liu, Y. L., Cawthorne, M. A., and Stock, M. J. (1996): / Br. J. Pharmacol., 117, 1355-361.
26. L?nnqvist, F., Krief, S., Strosberg, A. D., Nyberg, B., Emorine, L. J., and Arner, P. (1993): / Br. J. Pharmacol., 110, 929-36.
27. Milagro, F. I., Gómez-Ambrosi, J., Martínez-Anso, E., and Martínez, J. A. (1999): / J. Physiol. Biochem., 55, 25-1.
28. Moody, A. J., Stan, A. M., and Gliemann, J. (1974): / Horm. Metab. Res., 6, 12-6. CrossRef
29. Nantel, F., Bonin, H., Emorine, L. J., Zilberfarb, V., Strosberg, A. D., Bouvier, M., Marullo, S. (1993): / Mol. Pharmacol., 43, 548-55.
30. Nantel, F., Bonnin, H., Emorine, L. J., Zilberfarb, V., Strosberg, A. D., Bouvier, M. and Marullo, S. (1993): / Mol. Pharmacol., 43, 548-55.
31. Pott, C., Brixius, K., Bloch, W., Ziskoven, C., Napp, A., and Schwinger, R. H. (2006): / Pharmazie, 61, 255-60.
32. Sawa, M., and Harada, H. / Curr. Med. Chem. (2006): 13, 25-7. CrossRef
33. Strosberg, A. D., and Pietri-Rouxel. (1996): / Trends Pharmacol. Sci., 17, 373-81. CrossRef
34. Susulic, VS, Frederic, RC, Lawitts, J., Tozzo, E., Kahn, B. B., Harper, M. E., Himms-Hagen, J., Flier, J. S., and Lowell, B. B. (1995): / J. Biol. Chem., 270, 29483-9492. CrossRef
35. White, C. L., Ishihara, Y., Doston, T. L., Hughes, D. A., Bray, G. A., and York, D. A. (2004): / Physiol. Behav., 82, 489-96. CrossRef
36. Yoshida, T., Sakane, N., Wakabayashi, T., Umekawa, T., and Kondo, M. (1994): / Lif Sci., 54, 491-98. CrossRef - 作者单位：C. Ferrand (1)
A. Redonnet (1)
D. Prévot (2)
C. Carpéné (2)
C. Atgié (1)
1. DUSA, Université Bordeaux 1, Ave Michel Serres, 47 000, Agen, France
2. INSERM U586, Université Paul Sabatier, IFR 31, CHU Rangueil, Bat L3, 31432, Toulouse, France - ISSN：1877-8755
文摘
β3-adrenergic agonists have been considered as potent antiobesity and antidiabetic agents mainly on the basis of their beneficial actions discovered twenty years ago in obese and diabetic rodents. The aim of this work was to verify whether prolonged treatment with a β3-adrenergic agonist known to stimulate lipid mobilisation, could promote desensitization of β-adrenergic responses. Wistar rats and guinea pigs were treated during one week with CL 316243 (CL, 1 mg/kg/d) by implanted osmotic minipumps. In control animals, β3-adrenergic agonists were lipolytic in rat but not in guinea pig adipocytes. CL-treatment did not alter body weight gain in both species, but reduced fat stores in rats. Lipolysis stimulation by forskolin was unmodified but responses to β1-, β2- and β3-agonists were reduced in visceral or subcutaneous white adipose tissues of CL-treated rats. Similarly, the β3-adrenergic-dependent impairment of insulin action on glucose transport and lipogenesis in rat adipocytes was diminished after CL-treatment. In rat adipocytes, [125I]ICYP binding and β3-adrenoceptor mRNA levels were reduced after sustained CL administration. These findings show that CL 316243 exerts β3-adrenergic lipolytic and antilipogenic effects in rat adipocytes. These actions, which are likely involved in the fat depletion observed in rat, also lead to the desensitization of all β-adrenergic responses. Therefore this desensitization, together with the lack of slimming action in guinea pig, seriously attenuates the usefulness of β3-agonists as antiobesity agents, and may explain why such agonists have not been conducted to a widespread clinical, use.